Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.


Bain Capital Life Sciences

Foresite Capital

General Atlantic

venBio Partners

Venrock Healthcare Capital Partners

Kurma Partners

Venrock

Cormorant Asset Management

Viking Global Investors

Pharvaris

The Pharvaris team is onsite at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Meeting in Arlington, TX. Visit us at our booth and connect with our team Kenneth Robinson Amy DeWerth Wim Souverijns #HAE #deucrictibant #drugdevelopment

This afternoon, Pharvaris reported our fourth quarter and full year 2023 financial results and provided a business update. Highlights include enrollment in RAPIDe-3, scheduling an End-of-Phase 2 meetings to discuss development plan of deucrictibant for the prophylaxis of HAE attacks, strengthening the executive committee, and receipt of the UK Innovation Passport. #clinicaltrials #newhires #therapeuticinnovation 

Read the full press release here: https://lnkd.in/e2zGM6HB

Welcome, David Nassif, to the Pharvaris team! In the role of Chief Financial Officer, Mr. Nassif will be responsible for refining and implementing Pharvaris’ corporate #financialstrategy and activities including #financial #reporting and #operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial #management, #strategicplanning, #mergersandacquisitions, #investorrelations, #legal, and #capitalallocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies. Read the full press release here: https://lnkd.in/eRfP54vz

Stefan Abele, Pharvaris' Chief Technical Operations Officer and member of the board of the Division of Industrial and Applied Chemistry (DIAC) of the Swiss Chemical Society (SCS), recently published an open-access article in the Journal of the German Chemical Society GDCh. The article conveys the dynamic industry-academia ecosystem in Switzerland and displays DIAC's outreach and scope to spark inspiration. Read it here: https://lnkd.in/e-TzMbCQ or here: https://lnkd.in/gqPEg6hG

The Pharvaris team is looking forward to connecting with the HAE community at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference in Arlington, TX. Please feel free to connect with Kenneth Robinson, Amy DeWerth, or Wim Souverijns on site at our booth. Find more details on our #deucrictibant data presentation here: https://lnkd.in/eXCHS_jr

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
General Atlantic, L.P.	4.41M	2023-08-11	2.42M	1.99M	Shares	66.71M
Venbio Partners Llc	4.26M	2023-08-14	2.28M	1.99M	Shares	64.57M
Foresite Capital Management...	3.74M	2023-08-11	3.25M	496.52K	Shares	56.68M
Foresite Capital Management...	3.26M	2021-05-17	0	3.26M	Shares	91.27M
Bain Capital Life Sciences ...	3.18M	2022-11-14	3.18M	0	Shares	24.39M
Bain Capital Life Sciences ...	3.18M	2021-05-17	0	3.18M	Shares	88.99M
Fmr Llc	2.77M	2021-05-14	0	2.77M	Shares	77.66M
General Atlantic, L.P.	2.42M	2021-05-17	0	2.42M	Shares	67.72M
Viking Global Investors Lp	2.42M	2021-05-17	0	2.42M	Shares	67.91M
Venbio Partners Llc	2.30M	2021-05-17	0	2.30M	Shares	64.45M
Venbio Partners Llc	2.30M	2022-11-14	2.30M	-4.74K	Shares	17.62M
Vr Adviser, Llc	1.33M	2023-08-11	0	1.33M	Shares	20.08M
Deerfield Management Compan...	1.03M	2021-05-17	0	1.03M	Shares	28.90M
Vr Adviser, Llc	902.88K	2021-05-14	0	902.88K	Shares	25.34M
Cormorant Asset Management, Lp	864.14K	2021-05-17	0	864.14K	Shares	23.81M
Foresite Capital Management...	664.14K	2021-05-17	0	664.14K	Shares	18.58M
Pictet Asset Management Ltd	553.18K	2021-05-17	0	553.18K	Shares	15.52M
Eventide Asset Management, Llc	500K	2021-05-14	0	500K	Shares	14.03M
Avidity Partners Management Lp	400K	2021-05-17	0	400K	Shares	11.19M
Millennium Management Llc	230.90K	2021-05-17	0	230.90K	Shares	6.48M
Silverarc Capital Managemen...	200K	2023-08-14	559.39K	-359.39K	Shares	3.03M
Farallon Capital Management...	200K	2021-05-17	0	200K	Shares	5.61M
Novo Holdings A/S	50K	2021-05-17	0	50K	Shares	1.40M
Caas Capital Management Lp	50K	2021-05-17	0	50K	Shares	1.40M
Marshall Wace North America...	39.01K	2021-08-27	0	39.01K	Shares	1.09M
Foresite Capital Management...	34.14K	2022-11-14	34.14K	0	Shares	262K
Foresite Capital Management...	34.14K	2023-08-11	34.14K	0	Shares	516.91K
Blackrock Inc.	33.38K	2021-05-07	0	33.38K	Shares	934K
Perceptive Advisors Llc	27K	2021-08-13	0	27K	Shares	755K
Goldman Sachs Group Inc	24.43K	2021-05-17	0	24.43K	Shares	683K
Pinz Capital Management, Lp	22.65K	2021-05-17	0	22.65K	Shares	634K
Lynx1 Capital Management Lp	21.23K	2023-08-14	26.23K	-5K	Shares	321.35K
Geode Capital Management, Llc	16.38K	2021-05-12	0	16.38K	Shares	459K
Compagnie Lombard Odier Scma	15.03K	2021-04-23	0	15.03K	Shares	422K
Zimmer Partners, Lp	15K	2021-05-17	0	15K	Shares	420K
Jpmorgan Chase & Co	13.87K	2021-05-12	0	13.87K	Shares	389K
Ensign Peak Advisors, Inc	5K	2021-05-12	0	5K	Shares	140K
Morgan Stanley	4.83K	2021-05-17	0	4.83K	Shares	135K
Davidson Kempner Capital Ma...	3.50K	2021-05-17	0	3.50K	Shares	98K
Rokos Capital Management Llp	2.50K	2021-05-13	0	2.50K	Shares	68K
Bank Of America Corp /De/	500	2021-05-14	0	500	Shares	14K
Royal Bank Of Canada	116	2021-07-20	0	116	Shares	3K
Ubs Group Ag	32	2021-05-12	0	32	Shares	1K
Concourse Financial Group S...	0	2021-05-13	0	0	Shares	0

NASDAQ:PHVS

Pharvaris

Last Close

17.44

26/07 20:00

Market Cap

953.63M

Beta: −4.61

Volume Today

35.62K

Avg: 20.88K

PE Ratio

−14.74

PFCF: −13.89

Institutional trades

Institutional Ownership

Current holdings institutionals